Slightly too boosterish, in my opinion, but a fair look at almost all of the risks and upsides New Merck will likely face, through 2012 -- in a very long web-press-release (do go read it all):
. . . .With a new growth formula in place, a complimentary product portfolio and greater geographical reach, it will be a fresh start for the new Merck in the New Year. Merck, which has a strong balance sheet with cash and investments of about $8 billion, has already hinted that it is not going to be complacent about acquisitions and that it will be eyeing pipeline candidates with the greatest probability of success as well as licensing opportunities. This may be a good formula to solidify the company's position at the forefront of innovation and enhance its scientific and technological leadership. . . .
We shall see.
3 comments:
I'm sure it says nothing about their recent stature on a top ten list:
http://www.fiercepharma.com/special-reports/top-10-layoffs-2009
You are right -- layoffs, perhaps pushing above 17,000 in the coming year -- are not mentioned.
But without them, New Merck may sink under its own weight.
That is the saddest part of the Schering-Plough bust-up, in my opinion: it will be defined as a success, in large part by how many MORE people it puts out of gainful employment/career work.
Namaste
Ah, but when the overall climate is to 'get lean' what would we expect?
From a trade journal to the pharm executives.
http://pharmexec.findpharma.com/pharmexec/Strategy/Lean-Comes-to-Pharma/ArticleStandard/Article/detail/641195?contextCategoryId=48158
Right up Fred's direction.
Post a Comment